Conclusion and Implications
In conclusion, pirfenidone and nintedanib, either administered individually or in combination, exhibit remarkable potential in advanced silicosis mouse models. Further, combined therapy outperformed monotherapy even at a half dose. These therapeutic benefits are attributed to their influence on diverse signaling pathways and metabolic processes.
Keywords: silicosis, pulmonary fibrosis, pirfenidone, nintedanib, multi-omics.